Stopping GLP-1 drugs linked to twice the risk of heart attack, stroke or death in people with diabetes

Published 11 Nov 2026, 16:04 IST

What each side is saying

One outlet's own words from each side of the spectrum. Quoted, not summarised.

left · 1 outlet

An analysis of more than 80,000 people with type 2 diabetes in Italy found that those who discontinued GLP-1 receptor agonists had twice the risk of a combined outcome of non-fatal heart attack, non-fatal stroke or death from any cause compared with those who continued treatment. The post Stopping…

The South First
center · 1 outlet

An analysis of adults at increased risk of type 2 diabetes in India found that many underestimate their risk of the condition.

Hindustan Times

RSS excerpt

An analysis of more than 80,000 people with type 2 diabetes in Italy found that those who discontinued GLP-1 receptor agonists had twice the risk of a combined outcome of non-fatal heart attack, non-fatal stroke or death from any cause compared with those who continued treatment. The post Stopping…

Coverage arrived over 24 hours. First from Hindustan Times, latest from The South First.

Corroborated Coverage 2 news outlets reporting

Fact-Check & Bias Analysis

Reported by multiple independent newsrooms.

Coverage Bias Distribution

Based on 2 reporting publishers

L 50%

C 50%

Left / Center-Left 1 (50%)

Center 1 (50%)

Center-Right / Right 0 (0%)

Compare all reporting outlets (2)

Hindustan Times Center HT Media 10 Nov 2026, 15:38 IST

38.6 million adults in India have undiagnosed diabetes: Survey

An analysis of adults at increased risk of type 2 diabetes in India found that many underestimate their risk of the condition.

Compare on Varta → Read at Hindustan Times ↗
24 hours later
The South First Center-Left The South First Current article 11 Nov 2026, 16:04 IST

Stopping GLP-1 drugs linked to twice the risk of heart attack, stroke or death in people with diabetes

An analysis of more than 80,000 people with type 2 diabetes in Italy found that those who discontinued GLP-1 receptor agonists had twice the risk of a combined outcome of non-fatal heart attack, non-fatal stroke or death from any cause compared with those who continued treatment. The post Stopping…

Read at The South First ↗